JPH0314291B2 - - Google Patents
Info
- Publication number
- JPH0314291B2 JPH0314291B2 JP57172178A JP17217882A JPH0314291B2 JP H0314291 B2 JPH0314291 B2 JP H0314291B2 JP 57172178 A JP57172178 A JP 57172178A JP 17217882 A JP17217882 A JP 17217882A JP H0314291 B2 JPH0314291 B2 JP H0314291B2
- Authority
- JP
- Japan
- Prior art keywords
- tnf
- solution
- present
- activity
- substances
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 238000000034 method Methods 0.000 claims description 26
- 239000000126 substance Substances 0.000 claims description 21
- 206010028980 Neoplasm Diseases 0.000 claims description 16
- 201000011510 cancer Diseases 0.000 claims description 11
- 230000017074 necrotic cell death Effects 0.000 claims description 11
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 claims description 9
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 claims description 9
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 claims description 9
- WQZGKKKJIJFFOK-SVZMEOIVSA-N (+)-Galactose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-SVZMEOIVSA-N 0.000 claims description 8
- 229920001612 Hydroxyethyl starch Polymers 0.000 claims description 7
- 229940050526 hydroxyethylstarch Drugs 0.000 claims description 7
- 229920002307 Dextran Polymers 0.000 claims description 6
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 6
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 claims description 6
- SRBFZHDQGSBBOR-IOVATXLUSA-N D-xylopyranose Chemical compound O[C@@H]1COC(O)[C@H](O)[C@H]1O SRBFZHDQGSBBOR-IOVATXLUSA-N 0.000 claims description 4
- IAJILQKETJEXLJ-UHFFFAOYSA-N Galacturonsaeure Natural products O=CC(O)C(O)C(O)C(O)C(O)=O IAJILQKETJEXLJ-UHFFFAOYSA-N 0.000 claims description 4
- AEMOLEFTQBMNLQ-WAXACMCWSA-N alpha-D-glucuronic acid Chemical compound O[C@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O AEMOLEFTQBMNLQ-WAXACMCWSA-N 0.000 claims description 4
- SRBFZHDQGSBBOR-UHFFFAOYSA-N beta-D-Pyranose-Lyxose Natural products OC1COC(O)C(O)C1O SRBFZHDQGSBBOR-UHFFFAOYSA-N 0.000 claims description 4
- FZWBNHMXJMCXLU-BLAUPYHCSA-N isomaltotriose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@@H](OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O)O1 FZWBNHMXJMCXLU-BLAUPYHCSA-N 0.000 claims description 3
- 229940074410 trehalose Drugs 0.000 claims description 3
- 230000006641 stabilisation Effects 0.000 claims description 2
- 238000011105 stabilization Methods 0.000 claims description 2
- 229960002086 dextran Drugs 0.000 claims 1
- 230000000694 effects Effects 0.000 description 29
- 239000000243 solution Substances 0.000 description 26
- 210000004027 cell Anatomy 0.000 description 11
- 238000000746 purification Methods 0.000 description 10
- 206010028851 Necrosis Diseases 0.000 description 9
- 238000000338 in vitro Methods 0.000 description 9
- 238000003860 storage Methods 0.000 description 9
- 238000000926 separation method Methods 0.000 description 8
- 241000699670 Mus sp. Species 0.000 description 6
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 6
- 239000000203 mixture Substances 0.000 description 6
- 239000000843 powder Substances 0.000 description 6
- 238000004108 freeze drying Methods 0.000 description 5
- 239000002994 raw material Substances 0.000 description 5
- 230000000087 stabilizing effect Effects 0.000 description 5
- 241000124008 Mammalia Species 0.000 description 4
- -1 acetate ester Chemical class 0.000 description 4
- 239000002246 antineoplastic agent Substances 0.000 description 4
- 230000000052 comparative effect Effects 0.000 description 4
- 239000002158 endotoxin Substances 0.000 description 4
- 238000011156 evaluation Methods 0.000 description 4
- 238000009472 formulation Methods 0.000 description 4
- 230000002008 hemorrhagic effect Effects 0.000 description 4
- 238000001727 in vivo Methods 0.000 description 4
- 210000000865 mononuclear phagocyte system Anatomy 0.000 description 4
- 210000001519 tissue Anatomy 0.000 description 4
- 241000894006 Bacteria Species 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- 241000283973 Oryctolagus cuniculus Species 0.000 description 3
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 3
- 235000014680 Saccharomyces cerevisiae Nutrition 0.000 description 3
- 238000002835 absorbance Methods 0.000 description 3
- 239000000654 additive Substances 0.000 description 3
- 239000000872 buffer Substances 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- 238000007710 freezing Methods 0.000 description 3
- 230000008014 freezing Effects 0.000 description 3
- VEXZGXHMUGYJMC-UHFFFAOYSA-N hydrochloric acid Substances Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 3
- 239000002609 medium Substances 0.000 description 3
- CXKWCBBOMKCUKX-UHFFFAOYSA-M methylene blue Chemical compound [Cl-].C1=CC(N(C)C)=CC2=[S+]C3=CC(N(C)C)=CC=C3N=C21 CXKWCBBOMKCUKX-UHFFFAOYSA-M 0.000 description 3
- 229960000907 methylthioninium chloride Drugs 0.000 description 3
- 150000003839 salts Chemical class 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- 241001464975 Cutibacterium granulosum Species 0.000 description 2
- 241000192125 Firmicutes Species 0.000 description 2
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- 241000187654 Nocardia Species 0.000 description 2
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 2
- 206010039491 Sarcoma Diseases 0.000 description 2
- WNFHGZLVUQBPMA-JSCKKFHOSA-M Sodium glucuronate Chemical compound [Na+].O=C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)C([O-])=O WNFHGZLVUQBPMA-JSCKKFHOSA-M 0.000 description 2
- 239000013543 active substance Substances 0.000 description 2
- 230000001093 anti-cancer Effects 0.000 description 2
- 150000001720 carbohydrates Chemical class 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 230000001338 necrotic effect Effects 0.000 description 2
- 239000008363 phosphate buffer Substances 0.000 description 2
- 239000002504 physiological saline solution Substances 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 235000000346 sugar Nutrition 0.000 description 2
- 210000003462 vein Anatomy 0.000 description 2
- FZWBNHMXJMCXLU-UHFFFAOYSA-N 2,3,4,5-tetrahydroxy-6-[3,4,5-trihydroxy-6-[[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxymethyl]oxan-2-yl]oxyhexanal Chemical compound OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OCC(O)C(O)C(O)C(O)C=O)O1 FZWBNHMXJMCXLU-UHFFFAOYSA-N 0.000 description 1
- NHBKXEKEPDILRR-UHFFFAOYSA-N 2,3-bis(butanoylsulfanyl)propyl butanoate Chemical compound CCCC(=O)OCC(SC(=O)CCC)CSC(=O)CCC NHBKXEKEPDILRR-UHFFFAOYSA-N 0.000 description 1
- 206010003445 Ascites Diseases 0.000 description 1
- 241000193830 Bacillus <bacterium> Species 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 238000011740 C57BL/6 mouse Methods 0.000 description 1
- 241000700199 Cavia porcellus Species 0.000 description 1
- 241000186216 Corynebacterium Species 0.000 description 1
- 241000186427 Cutibacterium acnes Species 0.000 description 1
- LCGLNKUTAGEVQW-UHFFFAOYSA-N Dimethyl ether Chemical compound COC LCGLNKUTAGEVQW-UHFFFAOYSA-N 0.000 description 1
- 239000006145 Eagle's minimal essential medium Substances 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 description 1
- 102000008072 Lymphokines Human genes 0.000 description 1
- 108010074338 Lymphokines Proteins 0.000 description 1
- BAVYZALUXZFZLV-UHFFFAOYSA-N Methylamine Chemical compound NC BAVYZALUXZFZLV-UHFFFAOYSA-N 0.000 description 1
- 241000186359 Mycobacterium Species 0.000 description 1
- 241000589517 Pseudomonas aeruginosa Species 0.000 description 1
- 241000293871 Salmonella enterica subsp. enterica serovar Typhi Species 0.000 description 1
- 241000936695 Streptomyces gardneri Species 0.000 description 1
- 241000223997 Toxoplasma gondii Species 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- 206010054094 Tumour necrosis Diseases 0.000 description 1
- 229920000392 Zymosan Polymers 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 1
- BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical compound N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 description 1
- 229910052921 ammonium sulfate Inorganic materials 0.000 description 1
- 235000011130 ammonium sulphate Nutrition 0.000 description 1
- 239000003957 anion exchange resin Substances 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 159000000007 calcium salts Chemical class 0.000 description 1
- 230000005880 cancer cell killing Effects 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 229910002092 carbon dioxide Inorganic materials 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 229920001577 copolymer Polymers 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 229940119743 dextran 70 Drugs 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 239000012091 fetal bovine serum Substances 0.000 description 1
- 238000002523 gelfiltration Methods 0.000 description 1
- 229930182470 glycoside Natural products 0.000 description 1
- 230000009931 harmful effect Effects 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 125000004029 hydroxymethyl group Chemical group [H]OC([H])([H])* 0.000 description 1
- 238000004255 ion exchange chromatography Methods 0.000 description 1
- 239000000644 isotonic solution Substances 0.000 description 1
- 230000002147 killing effect Effects 0.000 description 1
- 229920006008 lipopolysaccharide Polymers 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 210000002751 lymph Anatomy 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 159000000003 magnesium salts Chemical class 0.000 description 1
- 201000004792 malaria Diseases 0.000 description 1
- MYWUZJCMWCOHBA-VIFPVBQESA-N methamphetamine Chemical compound CN[C@@H](C)CC1=CC=CC=C1 MYWUZJCMWCOHBA-VIFPVBQESA-N 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 244000045947 parasite Species 0.000 description 1
- 239000001103 potassium chloride Substances 0.000 description 1
- 235000011164 potassium chloride Nutrition 0.000 description 1
- 159000000001 potassium salts Chemical class 0.000 description 1
- 229940055019 propionibacterium acne Drugs 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 238000005185 salting out Methods 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 229920001059 synthetic polymer Polymers 0.000 description 1
- 238000010257 thawing Methods 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Landscapes
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Priority Applications (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP57172178A JPS5959625A (ja) | 1982-09-28 | 1982-09-28 | ガン壊死因子を安定化する方法 |
| US06/524,540 US4457916A (en) | 1982-08-31 | 1983-08-19 | Method for stabilizing Tumor Necrosis Factor and a stable aqueous solution or powder containing the same |
| IT67886/83A IT1200970B (it) | 1982-08-31 | 1983-08-23 | Procedimento per stabilizzare un fattore avente effetto necrotizzante sui tumori e soluzione aquosa stabile o polvere che lo contiene |
| DE3331003A DE3331003C2 (de) | 1982-08-31 | 1983-08-27 | Verfahren zur Stabilisierung des Tumor-Nekrose-Faktors und diesen enthaltende wäßrige Lösung oder Pulversubstanz |
| ES525228A ES8706446A1 (es) | 1982-08-31 | 1983-08-30 | Un metodo para preparar una solucion acuosa estable que contiene factor de necrosis de tumores. |
| FR8313971A FR2532178B1 (fr) | 1982-08-31 | 1983-08-31 | Procede pour stabiliser le facteur de necrose tumorale et solution aqueuse ou poudre stables contenant ce facteur |
| GB08323271A GB2126588B (en) | 1982-08-31 | 1983-08-31 | A method for stabilizing tumor necrosis factor and a stable aqueous solution or powder containing the same |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP57172178A JPS5959625A (ja) | 1982-09-28 | 1982-09-28 | ガン壊死因子を安定化する方法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPS5959625A JPS5959625A (ja) | 1984-04-05 |
| JPH0314291B2 true JPH0314291B2 (enrdf_load_stackoverflow) | 1991-02-26 |
Family
ID=15937016
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP57172178A Granted JPS5959625A (ja) | 1982-08-31 | 1982-09-28 | ガン壊死因子を安定化する方法 |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JPS5959625A (enrdf_load_stackoverflow) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS60260522A (ja) | 1984-06-07 | 1985-12-23 | Asahi Chem Ind Co Ltd | 遺伝子組換体が生産する生理活性物質の安定化法 |
| US4743680A (en) * | 1985-02-01 | 1988-05-10 | New York University | Method for purifying antihemophilic factor |
| JP2577743B2 (ja) * | 1986-07-18 | 1997-02-05 | 中外製薬株式会社 | 安定な顆粒球コロニ−刺激因子含有製剤 |
| CA1327161C (en) * | 1987-09-01 | 1994-02-22 | Mitsugu Kobayashi | Lyophilized pharmaceutical composition of neocarzinostatin derivative |
| EP1586329A1 (en) * | 2000-02-08 | 2005-10-19 | Allergan, Inc. | Botulinum toxin pharmaceutical compositions |
-
1982
- 1982-09-28 JP JP57172178A patent/JPS5959625A/ja active Granted
Also Published As
| Publication number | Publication date |
|---|---|
| JPS5959625A (ja) | 1984-04-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US4457916A (en) | Method for stabilizing Tumor Necrosis Factor and a stable aqueous solution or powder containing the same | |
| KR860000842B1 (ko) | 종양 괴사 인자의 안정화 방법 | |
| US4061537A (en) | Polyionic isotonic salt solution | |
| Van Zee et al. | Protection against lethal Escherichia coli bacteremia in baboons (Papio anubis) by pretreatment with a 55-kDa TNF receptor (CD120a)-Ig fusion protein, Ro 45-2081. | |
| CN1444442A (zh) | 用于生物材料的保存和贮存介质 | |
| JPS6310686B2 (enrdf_load_stackoverflow) | ||
| EP1220685B1 (en) | Pharmaceutical compositions of fibrinolytic agent | |
| IE60649B1 (en) | Mixed crystals of insulin and insulin derivatives, a process for the preparation of these mixed crystals, and pharmaceutical agents containing these mixed crystals | |
| JPH0314291B2 (enrdf_load_stackoverflow) | ||
| Raiha et al. | Effect of ethanol oxidation on levels of pyridine nucleotides in liver and yeast. | |
| FR2587216A1 (fr) | Composition pharmaceutique a base d'erythropoietine humaine destinee a etre administree par voie nasale pour le traitement de l'anemie | |
| US4966774A (en) | Superoxide dismutase composition | |
| JPH0375529B2 (enrdf_load_stackoverflow) | ||
| JPH0375530B2 (enrdf_load_stackoverflow) | ||
| Penttila et al. | Studies on the modification of the cellular response to injury: II. Electron microscopic studies on the protective effect of acidosis on anoxic injury of ehrlich ascites tumor cells | |
| CA2066532C (en) | Pharmaceutical compositions | |
| Van Dullemen et al. | Reduction of circulating secretory phospholipase A2 levels by anti-tumor necrosis factor chimeric monoclonal antibody in patients with severe Crohn's disease | |
| Kuhn et al. | Autoradiographic evidence for penetration of 3H-ceftriaxone (Rocephin®) into cells of spleen, liver and kidney of mice | |
| JPH0375531B2 (enrdf_load_stackoverflow) | ||
| JPH04198195A (ja) | Ｃｐｂ―ｉの安定化方法及び製剤組成物 | |
| McDonough et al. | Effects of endotoxin on the guinea pig heart response to ischemia reperfusion injury | |
| Nordstoga et al. | Porcine Salmonellosis: II. Production of the Generalized Shwartzman Reaction by Intravenous Injections of Disintegrated Cells of Salmonella Cholerae-Suis | |
| JPH02111726A (ja) | ヒト インターロイキン１を安定化する方法 | |
| JP3522798B2 (ja) | 糖修飾蛋白質の製造法 | |
| DE1617279A1 (de) | Verfahren zur Herstellung pharmazeutischer Praeparate zur Verhinderung der Bildung von Blutgerinnseln |